Research and Markets : Sales of Abarelix For the Treatment of Prostate Cancer Was Forecasted to Reach $450 million.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48492) has announced the addition of Prostate Cancer - A Therapeutic & Competitive Insight to their offering.

Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. Several new approvals have changed the panorama for options in the treatment of late stage prostate cancer. Abarelix was approved in November 2003 for the palliative treatment of men with advanced symptomatic prostate cancer. In May 2004 docetaxel was approved for use in combination with prednisone as a treatment for patients with androgen independent (hormone refractory) metastatic prostate cancer. Additionally, in October 2004 FDA approved histrelin for the palliative treatment of advanced prostate cancer. Finally, leuprolide was approved by FDA in January 2002 for the palliative treatment of advanced prostate cancer. One example of market penetration in this field is that analysts forecasts Abarelix a sales of $450 million in 2006.

Research and analysis highlights

In the report "Prostate Cancer - A Therapeutic & Competitive Insight" we do not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of prostate cancer therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future marketplace. We present both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report

* Thorough examination of status and impact of several novel drugs in development

* Discussion of the challenges in current and future treatment strategies

* Anticancer pipeline of most companies in the field

Key reasons to read this report

* Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in prostate cancer R&D, and the results of clinical trials to date

* Gain insight into the current challenges and commercial opportunities associated with prostate cancer therapy

* One hundred high quality references

Some of the drugs included in this analysis:

toremifene, bevacizumab, oblimersen sodium, R-flurbiprofen, sipuleucel-T, satraplatin, GVAX, exisulind, vapreotide, DCVax-prostate, epothilone D, ixabepilone, PTK/ZK, arsenic trioxide,retinoic acid, imatinib, bortezomib, sorafenib tosylate, doxorubicin etc.

Topics Covered

1 Executive Summary

2 Cancer Highlights

3 Methodology

4 Table of Contents

4.1 List of Boxes

4.2 List of Tables

5 Introduction

5.1 Disease Definitions

5.2 Etiology & Pathophysiology 

5.3 Epidemiology

5.4 Prognosis

6 Current Treatment Strategies

6.1 Localized Disease

6.1.1 Locally Advanced Prostate Cancer

6.2 Metastatic Prostate Cancer

6.2.1 Hormone-Sensitive Metastatic Prostate Cancer

6.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer

7 Progress in Current Treatment Strategies

7.1 Long-Term Follow-up Data not yet Been Published

7.2 Significant Reduced Risk of Distant Metastases 

7.3 Adverse Events

7.4 No Difference in Overall Survival

7.5 Cross-over Design an Optimal Option?

7.6 Death due to Liver Failure

7.7 Survival Benefit

7.8 Subdermal Implant

7.9 No FDA Approval

7.10 No Improvement in 5-year Disease-Free Survival

7.11 Effective Secondary Hormonal Therapy?

7.12 Synery in Combination

8 Key Therapeutic Strategies for Future Therapies

8.1 Therapeutic Type, Targets & Mechanisms

9 Competitive Landscape in Drug Development: The Late Stage Pipeline

9.1 Reduced Prostate Cancer Risk

9.2 High Activity in Metastatic AIPC Patients

9.3 Absence of Severe Toxicities

9.4 Waiting for Data

9.5 Probability of Regulatory Approval?

9.6 Co-development and License Agreement

9.7 Improves Predicted Survival?

9.8 Slow Progress & Development Partners

9.9 Exclusive License Agreement

10 Current Drug Development: The Early Stage Pipeline

10.1 New Data?

10.2 Terminated Study

10.3 More Than 50% PSA decline

10.4 Safety and Tolerability

10.5 Terminated

10.6 Marker of Drug Effect

10.7 Preliminary Results for a Tyrosine Kinase Inhibitor 

10.8 No Activity in Monotherapy

10.9 Dramatic Disappearance of Bone Metastatic Lesions

10.10 PSA Response - Anthracycline

11 Disclaimer

11.1 Liability

11.2 Completeness

12 Drug Index

13 Company Index

List of Boxes

List of Tables

Companies Mentioned Include:

- Orion Pharma - Genentech - Genta - Encore Pharmaceuticals - Dendreon - Johnson Matthey - Cell Genesys - OSI Pharmaceuticals - Debiopharm - Northwest Biotherapeutics - Kosan Biosciences - Bristol-Myers Squibb - Cephalon - Antigenics - Novartis - Millennium - Bayer - Johnson & Johnson

For more information visit http://www.researchandmarkets.com/reports/c48492